Skip to main content
Premium Trial:

Request an Annual Quote

Cirrex Claims Illumina's VeraCode Technology Infringes Patents

NEW YORK (GenomeWeb News) – Optical technology firm Cirrex Systems has filed a lawsuit against Illumina alleging infringement of three Cirrex patents through the sale of VeraCode microbeads.

Alpharetta, Ga.-based Cirrex filed its lawsuit last week in US District Court for the District of Delaware. In its complaint, it accused Illumina of infringing US Patent Nos. 6,542,673; 8,135,250; and 8,363,992.

All three patents apply to photonic technology that can be used in the life sciences for the detection and analysis of data from large volumes of samples. The '673 patent, titled "Identifier System and Components for Optical Assemblies," pertains to technology "for eliminating repeated testing of optical components while manufacturing an optical assembly [which] can include a high-performance optical component having a machine-readable identifier disposed within the peripheral area of its end face," according to the patent's abstract.

The '250 patent is titled "Facile Production of Optical Communication Assemblies and Components," and describes a micro-identifier system supporting "facile optical assemblies and components," the patent abstract said. The '992 patent, titled "Facile Optical Assemblies and Components," also relates to a micro-identification system that supports optical assemblies and components.

Cirrex said in its complaint that Illumina's VeraCode products — based on cylindrical glass microbeads — infringe all three patents. The VeraCode technology can be used to develop nucleic acid- and protein-based assays for a "broad range of applications," according to Illumina's website.

Cirrex has asked the court to find that Illumina infringes the patents and to issue a permanent injunction against further infringement by the San Diego-based firm. It also has asked for damages of an unspecified amount.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.